Redwood Invest Report
  • Business
  • Politics
  • Stocks
  • Investing
  • Business
  • Politics
  • Stocks
  • Investing

Redwood Invest Report

Investing

RAD Doses 1st Patient in Therapeutic Trial of 177Lu-RAD202

by admin June 4, 2025
June 4, 2025
RAD Doses 1st Patient in Therapeutic Trial of 177Lu-RAD202

Radiopharm Theranostics (RAD:AU) has announced RAD Doses 1st Patient in Therapeutic Trial of 177Lu-RAD202

Download the PDF here.

This post appeared first on investingnews.com

previous post
Operational Update
next post
Mali Court Adjourns Barrick’s Gold Complex Hearing Over Deepening Taxes, Control Dispute

Related Posts

Satellite Imagery and Gold Exploration

June 5, 2025

Ore Reserve Quadruples for Rhyolite Ridge Project; Reaffirms...

June 2, 2025

Harmony Gold to Acquire MAC Copper in US$1.03...

June 2, 2025

Scoping Study Demonstrates Low Cost Potential (Replacement)

June 5, 2025

Trailbreaker Resources Announces Exchange Approval Of COHO Property...

June 7, 2025

Silver Price Surges to US$36, Marking 13 Year...

June 6, 2025

Triumph Gold Announces the Acquisition of the Coyote...

June 4, 2025

US Capital Global Facilitates $50MM Financing to Accelerate...

June 7, 2025

Offer Booklet – Non-Renounceable Entitlement Offer

June 6, 2025

Wildfires Slash Canadian Oil Output by 7 Percent

June 5, 2025

Recent

  • Silver’s Surge is No Fluke—Here’s the Strange Ratio Driving It

  • Everyone Talks About Leaving a Better Planet for Our Children: Why Don’t We Leave Better Children for Our Planet?

  • Big Rally Ahead Should Yield All-Time High on This Index

  • Your Weekly Stock Market Snapshot: What It Means for Your Investments

  • From Tariffs to Tech: Where Smart Money’s Moving Right Now

  • Week Ahead: NIFTY’s Behavior Against This Level Crucial As The Index Looks At Potential Resumption Of An Upmove

Categories

  • Business (23)
  • Investing (59)
  • Politics (60)
  • Stocks (26)
  • About us
  • Contact us
  • Privacy Policy
  • Terms & Conditions

Copyright © 2025 redwoodinvestreport.com | All Rights Reserved